Results 121 to 130 of about 554,477 (299)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

FACULTY OF DENTAL SCIENCE MINUTE BOOKS

open access: yes, 1963
This record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete.
University Of Melbourne. Faculty Of Dental Science
core  

Biosphere: The Weekly Bulletin of Biology

open access: yes, 2009
Vol. VI, No. 15 | [Articles:] "Biology Students Achieve Campus-wide and State-wide\ud Recognition for their Research"; "Biology Department Graduate Award Winners"; "Faculty Research ...

core   +1 more source

Medical Students’ Perspective on the Effect of Sleep Quality on Academic Performance [Letter]

open access: yesAdvances in Medical Education and Practice, 2020
Oluwaseun Ikotun, Esther Wan Ching Lee, Michael Glover The University of Manchester, Faculty of Biology, Medicine and Health, Manchester, UKCorrespondence: Oluwaseun IkotunThe University of Manchester, Faculty of Biology, Medicine and Health, Manchester,
Ikotun O, Lee EWC, Glover M
doaj  

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

open access: yesMolecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir   +13 more
wiley   +1 more source

Bios: The Biology Department Newsletter - Fall 2005

open access: yes, 2005
Vol. XXI, No. 1 | [Articles:]"Biology Department Adds Three New Faculty Members"; "New Publications by Biology\ud Faculty and Their Students"; "Biology Students Honored"; "Research Talks and Posters\ud Presented at National Meetings"; "Do Prerequisites ...

core  

Observation and recording observations as a basis for biology teaching

open access: yes, 2021
Promatranje i opisivanje odnosa između prirodnih pojava i organizama temelji su istraživačke nastave u vertikali biološkog obrazovanja. Cilj ovog diplomskog rada jest procijeniti i usporediti sposobnost promatranja i bilježenja opažanja među studentima ...
Matić, Ana Marija
core  

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

open access: yesMolecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski   +12 more
wiley   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy